Hôpital Necker

Running trials

• Not yet recruiting

  Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy

  NCT07814001· Phase 2· Source

• Not yet recruiting

  Epidemiology of Invasive Bacterial Infections in Children With Sickle Cell Disease in France Between 2020 and 2025

  NCT07639008· Source

• Not yet recruiting

  Factors Associated With Blood Pressure Control Failure to Intravenous Labetalol in Severe Preeclampsia

  NCT07547046· Source

• Not yet recruiting

  Imlifidase for Highly Sensitized Kidney Transplant Recipients With a posItive crossmAtch Against a Deceased Donor: Results of Kidney Transplantations Performed in Accordance to the French Guidelines.

  NCT07379957· Source

• Active, not recruiting

  French Prospective Multicentric Study in Real World

  NCT07039942· Source

• Not yet recruiting

  Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)

  NCT06931704· Phase 2· Source

• Recruiting

  EWALL-PH OBSERVARTORY 2022

  NCT07684131· Source

• Recruiting

  A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

  NCT06084936· Phase 3· Source

• Recruiting

  Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination

  NCT05945524· Source

• Active, not recruiting

  Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients

  NCT06062537· Source

• Recruiting

  Engineering Immune Organoids to Study Pediatric Cancer

  NCT05890781· Source

• Active, not recruiting

  Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

  NCT04802590· Phase 2· Source

• Recruiting

  DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  NCT04920617· Phase 2· Source

• Active, not recruiting

  Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

  NCT04703192· Phase 2· Source

• Recruiting

  Creation of a Register of Patients With Neonatal-onset Epileptic Encephalopathy

  NCT04802135· Source

• Active, not recruiting

  Microbial Biomarkers of EArly Pseudomonas Aeruginosa Colonization in CHildren With Cystic Fibrosis

  NCT03947957· Source

• Active, not recruiting

  Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.

  NCT04144387· Source

• Recruiting

  Pediatric -Adult Care Transition Program of Patients With Sickle Cell Disease

  NCT03786549· Source

• Enrolling by invitation

  International Registry of Congenital Portosystemic Shunt (IRCPSS)

  NCT06041906· Source

• Active, not recruiting

  Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

  NCT00005584· Phase 3· Source

• Active, not recruiting

  RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease

  NCT00002462· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• High blood pressure2 recruiting
• Multiple myeloma2 recruiting
• Sickle cell disease2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Chronic kidney disease1 recruiting
• Epilepsy1 recruiting
• Follicular lymphoma1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Neuroblastoma1 recruiting
• Sarcoma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults

  NCT05923827· Source

• Completed

  Register of Patients With haEmophilia A tReated With Afstyla®

  NCT04675541· Source

• Completed

  Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL

  NCT03249870· Phase 2· Source

• Completed

  Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

  NCT02757989· Source

• Completed

  Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

  NCT02649790· Phase 1/2· Source

• Completed

  French Registry of First-line Treatment of Acute Promyelocytic Leukemia

  NCT02938858· Source

• Completed

  R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

  NCT01865110· Phase 3· Source